Twist Bioscience Corporation (TWST)

♥ 525 Thanks from members

Twist Bioscience (TWST) demonstrates strong top-line revenue growth driven by AI-enabled drug discovery and DNA synthesis, tempered by ongoing profitability hurdles, dilution risks from a $200 million ATM program, and speculative market volatility.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →

Other Nasdaq Tickers

NASDAQ

Microchip Technology Incorporated (MCHP)

NASDAQ

Direxion Daily AAPL Bear 1X ETF (AAPD)

NASDAQ

Ascentage Pharma Group International - American Depository Shares (AAPG)

NASDAQ

Direxion Daily AAPL Bull 2X ETF (AAPU)

NASDAQ

Alpha Blue Capital US Small-Mid Cap Dynamic ETF (ABCS)

NASDAQ

AbCellera Biologics Inc. - Common Shares (ABCL)

Entity & Market Metadata

Sector: Healthcare Industry: Biotechnology & Medical Research Founder: Emily Leproust Founder: Bill Bain Founder: Soren Skogstad Leadership: Emily Leproust (CEO) Leadership: Adam Clapper (CFO) Holder: Vanguard Group Holder: BlackRock Holder: Jennison Associates Synthetic Genes NGS Target Enrichment DNA Libraries Data Storage DNA #TWST #Twist Bioscience #Synthetic Biology #DNA Synthesis #Gene Sequencing